Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions.

ABSTRACT: Glioblastoma (GBM) remains the most lethal primary brain cancer with a median survival of under 2 years despite current best treatment practices. Early immunotherapies, including checkpoint blockade and vaccines, showed safety and immunogenicity but no survival benefit. Chimeric antigen receptor (CAR) T treatments in GBM trials have yielded feasibility and antitumor signals but still lack long-term control. This review synthesizes recent clinical and mechanistic data to establish priorities for clinical trial design, patient selection, and treatment development aimed at achieving durable responses in GBM.Recent trials highlight two consistent observations regarding the delivery of CAR T treatment. First, that CAR T cells can be effectively delivered peripherally rather than requiring direc

SUBMITTER: Walton CM 

PROVIDER: S-EPMC12581071 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature